- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Taysha Gene Therapies Inc (TSHA)Taysha Gene Therapies Inc stock price live, this page displays NASDAQ TSHA stock exchange data. View the TSHA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Taysha Gene Therapies Inc real time stock price chart below.
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 2.520.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock symbol for Taysha Gene Therapies Inc is "TSHA."
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
What Is the Taysha Gene Therapies Inc Stock Price Today?
The Taysha Gene Therapies Inc stock price today is 2.520.
What Is the Stock Symbol for Taysha Gene Therapies Inc?
The stock symbol for Taysha Gene Therapies Inc is "TSHA."
What Stock Exchange Does Taysha Gene Therapies Inc Trade On?
Taysha Gene Therapies Inc is listed and trades on the NASDAQ stock exchange.
Is Taysha Gene Therapies Inc a Good Stock to Buy?
Determining whether Taysha Gene Therapies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the TSHA quote. (ISIN: US8776191061)
2.520
-0.040(-1.56%)
Closed
After Hours
2.590+0.080(+3.187%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.470
2.680
52 wk Range
1.190
4.320
TSHA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.4702.680
52 wk Range
1.1904.320
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
TSHA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
6.591
Upside
+161.548%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Taysha Gene Company Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies Inc SWOT Analysis
Rett Syndrome Frontie | Taysha's TSHA-102 shows promise in treating Rett syndrome, targeting a $2.5 billion market with potential peak revenue of $1 billion by 2035 |
Clinical Progress | Phase 1/2 data reveals consistent improvements across Rett symptoms. Higher dose cohorts initiated early, with crucial data expected in H1 2025 |
Financial Outlook | $76.8M raised extends cash runway to Q4 2026. Analyst targets range from $5 to $7, reflecting cautious optimism amidst ongoing clinical development |
Regulatory Roadmap | RMAT designation may expedite approval. Key meetings with FDA in 2025 could accelerate TSHA-102's path to market, potentially outpacing competitors |
TSHA Full Pro Research
Institutional-Grade Stock Analysis
Understand how TSHA earns money
Financial health at a glance
Bearish and bullish outlooks
Latest expert insights
Actionable Pro Tips, and many more...
Gain access to 1400+ in-depth research reports on the most popular US stocks
Taysha Gene Therapies Inc Earnings Call Summary for Q3/2024
- TSHA-102 shows positive safety and efficacy in low-dose Rett Syndrome trials; high-dose cohort initiated and pediatric trial expanded to Canada
- Q1 financials: $15.1M R&D expenses, $20.9M net loss, $172.7M cash; runway extended to Q4 2026 through public offering
- Plans to report comprehensive data from high and low-dose cohorts in H1 2025; upcoming FDA discussions to refine trial design
- Transitioning to cohort-based updates; considering dosing schedule changes to accelerate trial timeline
Last Updated: 13-08-2024, 04:06 am
Read Full TranscriptCompare TSHA to Peers and Sector
Metrics to compare | TSHA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTSHAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −23.0x | −2.0x | −0.7x | |
PEG Ratio | −0.24 | −0.01 | 0.00 | |
Price/Book | 5.9x | 0.9x | 2.6x | |
Price / LTM Sales | 52.9x | 13.3x | 3.2x | |
Upside (Analyst Target) | 173.4% | 353.5% | 47.1% | |
Fair Value Upside | Unlock | 23.3% | 7.3% | Unlock |
Analysts' Recommendations
11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.591
(+161.54% Upside)
FAQ
What Is the Taysha Gene (TSHA) Stock Price Today?
The Taysha Gene stock price today is 2.52.
What Stock Exchange Does Taysha Gene Trade On?
Taysha Gene is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for Taysha Gene?
The stock symbol for Taysha Gene is "TSHA."
What Is the Taysha Gene Market Cap?
As of today, Taysha Gene market cap is 513.38M.
What is Taysha Gene Earnings Per Share?
The Taysha Gene EPS is -0.097.
What Is the Next Taysha Gene Earnings Date?
Taysha Gene will release its next earnings report on 25 Mar 2025.
From a Technical Analysis Perspective, Is TSHA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.